Wegovy 3.2mg: Why This Dose Isn't Part of the Licensed Schedule

The misconception: why people search for Wegovy 3.2mg

The 3.2mg figure isn't invented from nowhere. It appears in online forums and some overseas sources, often because people are conflating Wegovy's licensed schedule with a different semaglutide product, or with dose amounts used in compounded formulations that are not legal for supply in the UK. In other cases, the number crops up in discussions about mixing semaglutide from vials, and if you're curious what that process actually involves, our guide on how to mix semaglutide 2mg explains why it sits outside legitimate UK prescribing and has no place in regulated supply. Compounded or unlicensed versions of these medicines sit outside the regulated supply chain entirely.

The honest answer is straightforward: if a seller, website or social-media account describes a Wegovy 3.2mg product, that product does not correspond to anything with a UK marketing authorisation. Wegovy in the UK comes from Novo Nordisk in pre-filled pens at the five licensed strengths noted above, plus the newer 7.2mg pen. Nothing else is Wegovy. The MHRA has seized large quantities of fake weight-loss pens sold through unofficial channels, you can report suspect sellers via the Yellow Card scheme.

Worth knowing: the licensed schedule is deliberately incremental. The lower starting doses exist to let your body adjust; they are not weaker versions of a therapeutic effect but a built-in tolerability mechanism. Skipping steps or using non-standard strengths defeats that purpose and introduces genuine risk.

Wegovy's real dose steps and what they're each for

The titration works in roughly four-week blocks, moving from 0.25mg to 0.5mg, then 1.0mg, 1.7mg, and finally 2.4mg, the standard maintenance dose for which the original STEP 1 trial reported an average weight reduction of around 15% over 68 weeks, as published in the New England Journal of Medicine. Your prescriber decides whether and when to move up, and they may slow or pause titration if side effects are significant.

The 7.2mg maintenance dose, approved by the MHRA on 14 April 2026, is now the ceiling. In the trials supporting that approval, average weight loss approached around 20.7% over 72 weeks, narrowing the gap with tirzepatide's results at higher doses. That approval is for adults with a BMI of 30 or above and is reached by working through the same titration ladder; it is not a shortcut. If you want to understand how the two maintenance-dose options compare, the Wegovy treatment overview sets them out clearly.

A prescriber, not the patient, decides the pace. That matters because GI side effects (nausea, loose stools, reflux) are most likely to appear after a step up, and a well-managed titration keeps them manageable. Pushing the pace to reach a higher number faster isn't a clinical strategy; it's just more discomfort for no demonstrated benefit.

What if you're already on 2.4mg and want to know about going further?

If you're currently on the 2.4mg maintenance dose and your prescriber believes 7.2mg is appropriate, that progression follows the same clinical review process, it doesn't happen automatically. The 7.2mg pen is a dedicated device with an auto-dosing mechanism and a built-in covered needle that locks after use. When it arrives through a regulated pharmacy, it comes in plain, unbranded packaging via tracked DPD delivery, the same discreet route as any other dose.

People who have already established a 2.4mg weekly-injection routine and are being considered for 7.2mg are assessed individually. The MHRA's approval specifically covers BMI 30 or above and does not extend to the cardiovascular indication. A page on the next steps in Wegovy dosing covers this territory in more detail for readers who are partway through treatment.

For anyone earlier in their journey, the step up to the 2mg range is often where people start to notice the most meaningful appetite change, a question our prescribers hear most weeks. The right dose for you is a clinical judgement, not a number to optimise alone. For a broader sense of what semaglutide does and how it works, the semaglutide overview is the place to start.

What a legitimate Wegovy prescription looks like in practice

A prescription for Wegovy in the UK must come from a registered prescriber following a clinical assessment. That assessment covers your BMI, medical history, any medicines you already take, and whether weight management treatment is appropriate for you. BMI eligibility for the licensed indication sits at 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance.

On treatment cost, private Wegovy prescriptions vary by dose and provider. Since Eli Lilly's list-price revision in September 2025 prompted wider market movement, typical private monthly prices across providers have ranged roughly £149–£375 depending on dose and service. The weight-loss treatments page sets out how pricing works at nume and what a single transparent fee actually covers.

Any pharmacy supplying a prescription medicine online should appear on the GPhC register, which you can check at pharmacyregulation.org/registers. A seller offering semaglutide in unlicensed strengths, without a prescription, or at prices that sit suspiciously far below the market is not operating within the UK regulatory framework. That is not a minor technicality, it is a direct patient safety issue. If you want to understand how the private consultation route works in practice, the guide to accessing Wegovy through a private pharmacy covers each step, and the about us page explains how our clinical team is set up.